What histoprognostic factors are useful in making a therapeutic decision in colonic cancer?;Quels sont les facteurs histo-pronostiques utiles a la decision therapeutique dans les cancers du colon?

Gastroenterologie Clinique et Biologique

Volumn 22, Issue 3 BIS, 1998, Pages

  Piard, Françoise ^a   Monges, Geneviève ^b  

^a UNIVERSITÉ DE BOURGOGNE   (France)

^b INSTITUT PAOLI CALMETTES   (France)

Author keywords

Classifications; Colonic cancer; Genetic alterations; Prognosis

Indexed keywords

CANCER CLASSIFICATION; CANCER GENETICS; COLON CANCER; CONFERENCE PAPER; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; PROGNOSIS;

COLONIC NEOPLASMS; HUMANS; NEOPLASM STAGING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0031809389     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (97)

1. Bosman FT. Prognostic value of pathological characteristics of colorectal cancer. Eur J Cancer 1995;31A:1216-21.
2. Deans GT, Parks TG, Rowlands BJ, Spence RAJ. Prognostic factors in colorectal cancer. Br J Surg 1992;79:608-13.
3. Maurel J. Facteurs de pronostic du cancer colorectal. In: Faivre J, Gignoux M, eds. Tumeurs colorectales. Progrès en HépatoGastroentérologie. Paris: Doin, 1995;10:195-207.
4. Conroy T, Guillemin F, Stines J, Denis B. Diagnostic et évaluation de l'extension des cancers colorectaux. Rev Prat 1994;44:2706-13.
5. Williams ST, Beart RW. Staging of colorectal cancer. Semin Surg Oncol 1992;8:89-93.
6. Dukes CE. The classification of cancer of the rectum. J Pathol 1932;35:323-32.
7. Gunderson LL, Sosin H. Areas of failure found at reoperation (second or symptomatic look) following «curative surgery »for adenocarcinoma of the rectum. Clinicopathology correlations and implications for adjuvant therapy. Cancer 1974;34:1278-92.
8. Astler VB, Coller FA, Arbor A. The pronostic significance of direct extension of carcinoma of the colon and rectum. Ann Surg 1954;139:846-52.
9. Hermanek P, Hutter RVP, Sobin LH, Wagner G, Wittekind Ch. TNM Atlas Illustrated Guide to the TNM/pTNM classification of malignant tumors. 4th edition. New York, Berlin, Heidelberg: Springer, 1997.
10. Sobin LH, Wittekind Ch. International Union Against Cancer (UICC). TNM classification of malignant tumors. 5th edition. New York: John Wiley & Sons, 1997.
11. Newland RC, Dent OF, Lyttle MNB, Chapuis PH, Bokey EL. Pathologic determinants of survival associated with colorectal cancer with lymph node metastases. Cancer 1994;73:2076-82.
12. Goldstein NS, Sanford W, Coffey M, Layfield LJ. Lymph node recovery from colorectal resection specimens removed for adenocarcinoma. Trends over time and a recommendation for a minimum number of lymph nodes to be recovered. Am J Clin Pathol 1996;106:209-16.
13. Michiels C, Boutron MC, Chatelain N, Quipourt V, Roy P, Faivre J. Facteurs pronostiques des adénocarcinomes colorectaux de stade B de Dukes. Gastroenterol Clin Biol 1994;18:456-61.
14. Adell G, Boeryd B, Franlund B, Sjödahl R, Hakansson L. Occurrence and prognostic importance of micrometastases in regional lymph nodes in Dukes'B colorectal carcinoma: an immunohistochemical study. Eur J Surg 1996;162:637-42.
15. Cutait R, Alves VAF, Lopes LC, Cutait DE, Borges JLA, Singer J, et al. Restaging of colorectal cancer based on the identification of lymph node micrometastases through immunoperoxidase staining of CEA and cytokeratins. Dis Colon Rectum 1991;34:917-20.
16. Jeffers MD, O'Dowd GM, Mulcahy H, Stagg M, O'Donoghue DP, Toner M. The prognostic significance of immunohistochemically detected lymph node micrometastases in colorectal carcinoma. J Pathol 1994;172:183-7.
17. Greenson JK, Isenhart CE, Rice R, Mojzisik C, Houchens D, Martin EW. Identification of occult micrometastases in pericolic lymph nodes of Dukes'B colorectal cancer patients using monoclonal antibodies against cytokeratin and CC49. Cancer 1994;73:563-9.
18. Philipps RKS. Adequate distal margin of resection for adenocarcinoma of the rectum. World J Surg 1992;16:463-6.
19. Sondenaa K, Kjellevold KJ. A prospective study of the lengh of the distal margin after low resection for rectal cancer. Int J Colored Dis 1990;5:103-5.
20. Quirke P, Dixon MF. The prediction of local recurrence in rectal adenocarcinoma by histopathological examination. Int J Colorect Dis 1988;3:127-31.
21. Shepherd NA, Baxter KJ, Love SB. The prognostic importance of peritoneal involvement in colonic cancer: a prospective evaluation. Gastroenterology 1997;112:1096-102.
22. Hermanek P, Guggenmoos-Holzmann F, Gall FP. Prognotic factors in rectal carcinoma. A contribution to the further development of tumour classification. Dis Colon Rectum 1989;32:593-9
23. Shepherd NA, Saraga EP, Love SB, Jass JR. Prognostic factors in colonie cancer. Histopathology 1989;14:613-20.
24. Bruine de AP, Wiggers T, Beek C. Endocrine cells in colorectal adenocarcinomas: incidence, hormone profiles and prognostic relevance. Int J Cancer 1993;54:765-71.
25. Ferrero S, Buffa R, Pruneri G, Siccardi AG, Pelagi M, Lee AKC, et al. The prevalence and clinical significance of chromogranin A and secretogranin II immunoreactivity in colorectal adenocarcinomas. Virchows Arch 1995;426:587-92.
26. Hamada Y, Oishi A, Shoji T, Takada H, Yamamura M, Hioki K, et al. Endocrine cells and prognosis in patients with colorectal carcinoma. Cancer 1992;69:2641-6.
27. Lapertosa G, Baracchini P, Delucchi F. Prevalence and prognostic significance of endocrine cells in colorectal adenocarcinomas. Pathologica 1994;86:170-3.
28. Hase K, Shatney C, Johnson D. Prognostic value of tumor « budding »in patients with colorectal cancer. Dis Colon Rectum 1993;36:627-35.
29. Jass JR, Atkin WS, Cuzick J, Bussey HJR, Morson BC, Northover JMA, et al. The grading of rectal cancer: historical perspectives and a multivariate analysis of 447 cases. Histopahology 1986;10:437-59.
30. Minsky BD, Mies C, Rich TA, Recht A, Chaffey JT. Potentially curative surgery of colon cancer: the influence of blood vessel invasion. J Clin Oncol 1988;6:119-27.
31. Tsuchiya A, Ando Y, Kiruchi Y, Kanazawa M, Sato H, Abe R. Venous invasion as a prognostic factor in colorectal cancer. Jpn J Surg 1995;25:950-3.
32. Krasna MJ, Flancbaum L, Cody RP, Shneibaum S, Ben Ari G. Vascular and neural invasion in colorectal carcinoma. Incidence and prognostic significance. Cancer 1988;61:1018-23.
33. Ouchi K, Sugawara T, Ono H, Fujiya T, Kamiyama Y, Kakugawa Y, et al. Histologic features and clinical significance of venous invasion in colorectal carcinoma with hepatic metastasis. Cancer 1996;78:2313-7.
34. Yamazoc Y, Mactani S, Onodera H, Nishikawa T, Tobe T. Histopathological prediction of liver metastasis after curative resection of colorectal cancer. Surg Oncol 1992;1:237-44.
35. Engel CJ, Bennett ST, Chambers AF, Doig GS, Kerkvliet N, O'Malley FP. Tumor angiogenesis predicts recurrence in invasive colorectal cancer when controlled for Dukes staging. Am J Surg Pathol 1996;20:1260-5.
36. Mooteri S, Rubin D, Leurgans S, Jakate S, Drab E, Saclarides T. Tumor angiogenesis in primary and metastatic colorectal cancers. Dis Colon Rectum 1996;39:1073-80.
37. Tanigawa N, Amaya H, Matsumura M, Lu C, Kitaoka A, Matsuyama K, et al. Tumor angiogenesis and mode of metastasis in patients with colorectal cancer. Cancer Res 1997;57:1043-6.
38. Harrison JC, Dean PJ, El-Zeky F, Van Der Zwaag R. Impact of the Crohn's-like lymphoid reaction on staging of right-sided colon cancer: results of multivariate analysis. Hum Pathol 1995;26:31-8.
39. Jass JR, Ajioka Y, Allen JP, Chan YF, Cohen RJ, Nixon JM, et al. Assessment of invasive growth pattern and lymphocytic infiltration in colorectal cancer. Histopathology 1996;28:543-8.
40. Dean PA, Vernava AM. Flow cytometric analysis of DNA content in colorectal carcinoma. Dis Colon Rectum 1992;35:95-102.
41. Scott NA, Wiegand HS, Moertel CG, Cha SS, Beart RW, Lieber MM. Colorectal cancer: Dukes stage, tumor site, preoperative plasma CEA level, and patient prognosis related to tumor DNA ploidy pattern. Arch Surg 1987;122:1375-9.
42. Kokal WA, Gardine RI, Sheibani K, Morris PL, Prager E, Zak IW, et al. Tumor DNA content in resectable primary colorectal carcinoma. Ann Surg 1989;209:188-93.
43. Witzig TE, Loprinzi CL, Gonchoroff NJ, Reiman RM, Cha SS, Wieand HS, et al. DNA ploidy and cell kinetic measurements as predictors of recurrence and survival in stage B2 and C colorectal adenocarcinoma. Cancer 1991;68:879-88.
44. Laurent-Puig P, Olschwang S, Delattre O, Remvikos Y, Asselain B, Melot B, et al. Survival and acquired genetic alterations in colorectal cancer. Gastroenterology 1992;102:1136-41.
45. Kato M, Saji S, Tsuya H, Miya K, Fukada D, Umemoto T, et al. Clinical study of the relationship between cytological behavior and postoperative prognosis in colorectal cancer cases with special reference to nuclear DNA content and nucleolar organizer regions. J Surg Oncol 1997;64:36-41.
46. Pinto AE, Chaves P, Fidalgo P, Oliveira AG, Leitao CN, Soares J. Flow cytometric DNA ploidy and S-phase fraction correlate with histopathologic indicators of tumor behavior in colorectal carcinoma. Dis Colon Rectum 1997;40:411-9.
47. Deams GT, Williamson K, Hamilton P, Heatley M, Arthurs K, Patterson CC, et al. DNA densitometry of colorectal cancer. Gut 1993;34:1566-71.
48. Tomita T. DNA ploidy and proliferating cell nuclear antigen in colonic adenomas and adenocarcinomas. Dig Dis Sci 1995;40:996-1004.
49. Offerhaus GJA, De Feyter EP, Cornelisse CJ, Tersmette KWF, Floyd J, Kern SE, et al. The relationship of DNA aneuploidy to molecular genetic alterations in colorectal carcinomas. Gastroenterology 1992;102:1612-9.
50. Saccani-Jotti G, Fontanesi M, Orsi N, Sarli L, Pietra N, Peracchia A, et al. DNA content in human colon cancer and non-neoplastic adjacent mucosa. Int J Biol Markers 1995;10:11-6.
51. Pietra N, Sarli L, Sansebastiano G, Jotti GS, Peracchia A. Prognostic value of ploidy, cell proliferation kinetics, and conventional clinicopathologic criteria in patients with colorectal carcinoma. A prospective study. Dis Colon Rectum 1996;39:494-503.
52. Zarbo RJ, Nakhleh RE, Brown RD, Kubus JJ, Ma CK, Mackowiak P. Prognostic significance of DNA ploidy and proliferation in 309 colorectal carcinomas as determined by two-color multiparametric DNA flow cytometry. Cancer 1997;79:2073-86.
53. Chapman MAS, Hardcastle JD, Armitage NCM. Five-year prospective study of DNA tumor ploidy and colorectal cancer survival. Cancer 1995;76:383-7.
54. Nori D, Merimsky O, Samala E, Saw D, Cortes E, Chen E, et al. Tumor ploidy as a risk factor for disease recurrence and short survival in surgically-treated Dukes'B2 colon cancer patients. J Surg Oncol 1995;59:239-42.
55. Jones DJ, Moore M, Schofield PF. Refining the prognostic significance of DNA ploidy status in colorectal cancer: a prospective flow cytometric study. Int J Cancer 1988;41:206-10.
56. Dix BR, Robbins P, Soong R, Jenner D, House AK, Iacopetta BJ. The common molecular genetic alterations in Dukes'B and C colorectal carcinomas are not short-term prognostic indicators of survival. Int J Cancer 1994;59:747-51.
57. Jen J, Kim H, Piantadosi S, Liu ZF, Levitt RC, Sistonen P, et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 1994;331:213-21.
58. Shibata D, Reale MA, Lavin P, Silverman M, Fearon ER, Steele G, et al. The DCC protein and prognosis in colorectal cancer. N Engl J Med 1996;335:1727-32.
59. Kern SE, Fearon ER, Tersmette KWF, Enterline JP, Leppert M, Nakamura Y, et al. Allelic loss in colorectal carcinoma. JAMA 1989;261:3099-103.
60. Kochhar R, Hailing KC, McDonnell S, Schaid DJ, French AJ, O'Connell MJ, et al. Allelic imbalance and microsatellite instability in resected Duke's D colorectal cancer. Diagn Mol Pathol 1997;6:78-84.
61. Hamelin R, Laurent-Puig P, Olschwang S, Jego N, Asselain B, Remvikos Y, et al. Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 1994;106:42-8.
62. Leahy DT, Salman R, Mulcahy H, Sheahan K, O'Donoghue DP, Parfrey NA. Prognostic significance of p53 abnormalities in colorectal carcinoma detected by PCR-SSCP and immunohistochemical analysis. J Pathol 1996;180:364-70.
63. Bell SM, Scott N, Cross N, Sagar P, Lewis FA, Blair GE, et al. Prognostic value of p53 overexpression and c-Ki-ras mutations in colorectal cancer. Gastroenterology 1993;104:57-64.
64. Mulder JWR, Baas IO, Polak MM, Goodman SN, Offerhaus GJA. Evaluation of p53 protein expression as a marker for long-term prognosis in colorectal carcinoma. Br J Cancer 1995;71:1257-62.
65. Costa A, Marasca R, Valentinis B, Savarino M, Faranda A, Silvestrini R, et al. p53 gene point mutations in relation to p53 nuclear protein accumulation in colorectal cancers. J Pathol 1995;176:45-53.
66. Campo E, Calle-Martin O, Miquel R, Palacin A, Romero M, Fabregat V, et al. Loss of heterozygosity of p53gene and p53 protein expression in human colorectal carcinomas. Cancer Res 1991;51:4436-42.
67. Yamaguchi A, Nakagawara G, Kurosaka Y, Nishimura G, Yonemura Y, Miyazaki I. p53 immunoreaction in endoscopic biopsy specimens of colorectal cancer, and its prognostic significance. Br J Cancer 1993;68:399-402.
68. Auvinen A, Isola J, Visakorpi T, Koivula T, Virtanen S, Hakama M. Overexpression of p53 and long-term survival in colon carcinoma. Br J Cancer 1994;70:293-6.
69. Tomoda H., Kareji Y. Immunohistochemical analysis of p53 in colorectal cancer regarding clinicopathological correlation and prognostic significance. J Surg Oncol 1995;58:125-8.
70. Tominaga O, Salmon R-J, Laurent-Puig P. Gène TP53 et cancers digestifs. Gastroenterol Clin Biol 1993;17:187-96.
71. Gang O, Ahnen D, Fenoglio-Preiser C, Loll L, Bunn P, Feigl P. K-ras mutation and p53 overexpression but not ploidy status predict the clinical behavior of colon cancer (abstract). Gastroenterology 1996;110:A516.
72. Pereira H, Silva S, Juliâo R, Garcia P, Perpétua F. Prognostic markers for colorectal cancer: expression of p53 and Bcl2. Word J Surg 1997;21:210-3.
73. Starzynska T, Bromley M, Mariiez K, Roberts SA, Ucinski M, Stern PL. Accumulation of p53 in relation to long-term prognosis in colorectal carcinoma. Eur J Gastroenterol Hepatol 1997;9:183-6.
74. Baas IO, Mulder JWR, Offerhaus GJA, Vogelstein B, Hamilton SR. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994;172:5-12.
75. Wynford-Thomas D. p53 in tumour pathology: can we trust immunocytochemistry ? J Pathol 1992;166:329-33.
76. Hall PA, Lane DP. p53 in tumour pathology: can we trust immunohistochemistry? revisited! J Pathol 1994;172:1-4.
77. Dix BR, Robbins P, Carrello S, House A, Iacopetta B. Comparison of p53 gene mutation and protein overexpression in colorectal carcinomas. Br J Cancer 1994;70:585-90.
78. Kastriwakis WV, Ramchurren N, Maggard M, Steele G, Summerhayes IC. K-ras status does not predict successful hepatic resection of colorectal cancer metastasis. Arch Surg 1995;130:9-14.
79. Pricolo VE, Finkelstein SD, Wu TT, Keller G, Bakker A, Swalsky PA, et al. Prognostic value of TP53 and K-ras-2 mutational analysis in stage III carcinoma of the colon. Am J Surg 1996;171:41-6.
80. Norheim Andersen S, Lovig T, Breivik J, Lund E, Gaudemack G, Meling GI, et al. K-ras mutations and prognosis in large-bowel carcinomas. Scand J Gastroenterol 1997;32:62-9.
81. Benhattar J, Losi L, Chaubert P, Givel JC, Costa J. Prognostic significance of K-ras mutations in colorectal carcinoma. Gastroenterology 1993;104:1044-8.
82. Hayashi N, Ito I, Yanagisawa A, Kato Y, Nakamori S, Imaoka S et al. Genetic diagnosis of lymph-node metastasis in colorectal cancer. Lancet 1995;345:1257-9.
83. Hayashi N, Arakawa H, Nagase H, Yanagisawa A, Kato Y, Ohta Y, et al. Genetic diagnosis identifies occult lymph node metastasis undetectable by the histopathological method. Cancer Res 1994;54:3853-6.
84. Wang L, Patel U, Ghosh L, Chen HC, Barnerjee S. Mutation in the nm23 gene is associated with metastasis in colorectal cancer. Cancer Res 1993;53:717-20.
85. Cohn KH, Wang F, Desoto-Lapaix F, Soloman WV, Patterson LG, Arnold MR, et al. Association of nm23-H1 allelic deletions with distant metastases in colorectal carcinoma. Lancet 1991;338:722-4.
86. Heide I, Theide C, Poppe K, De Kant E, Huhn D, Rochlitz C. Expression and mutational analysis of Nm23-H1 in liver metastases of colorectal cancer. Br J Cancer 1994;70:1267-71.
87. Campo E, Miquel R, Jares P, Bosch F, Juan M, Leone A, et al. Prognostic significance of the loss of heterozygosity of Nm23-H1 and p53 genes in human colorectal carcinomas. Cancer 1994;73:2913-21.
88. Wielenga VJM, Heider KH, Offermans GJA, Adolf GR, Van Den Berg FM, Ponta H, et al. Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res 1993;53:4754-6.
89. Mulder JWR, Kruyt PM, Sewnath M, Oosting J, Seldenrijk CA, Weidema WF, et al. Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. Lancet 1994;344:1470-2.
90. Finke LH, Terpe JH, Zörb C, Haensch W, Schlag PM. Colorectal cancer prognosis and expression of exon v6 containing CD44 proteins. Lancet 1995;345:583.
91. Laurent-Puig P. Valeur pronostique des altérations génétiques des cancers colorectaux. Gastroenterol Clin Biol 1996;20;B27-B35.
92. Kim H, Jen J, Vogelstein B, Hamilton SR. Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol 1994;145:148-56.
93. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993;260:816-9.
94. Hamelin R, Laurent-Puig P, Olschwang S, Jego N, Salmon RJ, Thomas G. Genetic instability of microsatellites in human colon cancer (abstract). Gastroenterology 1994;106:A390.
95. Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark N, Drake JC, et al. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994;12:2640-7.
96. Lenz HJ, Danenberg KD, Danenberg P, Johnston P, Florentine B, Leichman CG, et al. p53 status and thymidylate synthase (TS) expression are associated and predict for recurrence in patients with stage II colon cancer (CC) (abstract). Proc Am Soc Clin Oncol 1996;15:215.
97. Delattre O, Law DJ, Remvikos Y, Sastre X, Feinberg AP, Olschwang S, et al. Multiple genetic alterations in distal and proximal colorectal cancer. Lancet 1989;12:353-5.